Optovue Corporation is an ophthalmic device company dedicated to working with eye care professionals and clinical researchers to lead the commercialization of new imaging modalities that improve diagnosis and therapy of ocular disease.
Incorporated in December 2003 and located in Fremont California, Optovue was founded by pioneers of Optical Coherence Tomography to develop the next generation ophthalmic diagnosis instrument based on the Fourier-Domain OCT technology. The ultra-high speed high resolution FD-OCT provides physicians with advanced retina diagnostic capabilities that will have significant benefit for patients who have retina conditions such as macular degeneration, diabetic retinopathy, glaucoma, and other macular diseases.
The Optovue team is composed of seasoned professionals experienced in the design, development, production, marketing, and sales of ophthalmic devices. Optovue is assisted by a Scientific and Medical Advisory Board composed of leaders in advanced OCT technology and ocular disease treatment. The company received FDA clearance for the RTVue retina scanner in October 2006, and a compact portable OCT, iVue, in 2010.
Optovue has been the fast growing company in the ophthalmic device industry. Since the launch of the RTVue to market in 2006, the company has grown to 140 employees, with a total of more than 3400 RTVue and iVue systems installed worldwide. Optovue has been continuously profitable since Oct 2007.
Optical Coherence Tomography has emerged from a new imaging modality to a standard ocular diseases diagnostic tool. The OCT technology and clinical evolution will prevail in ophthalmic imaging like MRI in brain imaging and CT in heart imaging.
Optovue’s goal is to lead the commercialization of new imaging modalities that improve diagnosis and therapy of ocular diseases.
We are committed to working with physicians to make the technology work for clinics, and most importantly to benefit patients.